Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share.

Upstream Bio, Inc. declined 4.98% in premarket trading. HBM Healthcare Investments, which holds an international portfolio of promising companies in the human medicine, biotechnology, medical technology, and diagnostics sectors, reported a decline of 8.4% in its quarterly NAV per share. Additionally, HBM Healthcare Investments swung to a Q1 loss, which could have negatively impacted investor sentiment towards Upstream Bio, Inc.